The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
For these reasons, double blinding, in which neither the subject nor the person who assesses the drug's effect is aware of the subject's treatment group, is particularly important in cannabinoid drug studies. Another important control for subjective effects includes the use of placebo drugs, which are inert substances, or the use of comparison drugs that have effects similar to the experimental drug. Finally, the quality of the experimental design depends on controlling for factors that are unrelated to the test drug but that might nonetheless influence the treatment outcome. Sequencing effects are one example of such factors. For example, patients might react differently to the same medication depending on whether the medication was administered after an effective or an ineffective treatment. Likewise, a patient whose symptoms are initially mild might react differently to a drug than would a patient whose symptoms are initially severe. Because psychological effects are associated with cannabinoid drugs, it is important to consider how such side effects might influence the therapeutic value of the treatment. Conditions such as pain and nausea are especially susceptible to subjective influences. For example, depending on the person, THC can reduce or increase anxiety; it is important to determine to what extent this ''side effect'' contributes to the therapeutic effect.
While double-blind, randomized, controlled clinical trials offer the highest degree of assurance of drug efficacy, such trials are not always feasible. Vulnerable populations, such as children, older patients, and women of child-bearing age, are often excluded from experimental drug trials for safety reasons. Nonetheless, such patients are part of everyday clinical practice. The challenge of integrating the ideal of standardized and rigorous processes for treatment evaluation with everyday clinical practice has encouraged interest in single-patient trials.67 Methods for such trials have been established and tested in a variety of clinical settings, usually under everyday conditions.66,105,159 They are particularly valuable when physicians or patients are uncertain about the efficacy of treatment for symptomatic diseases. Controls can be incorporated even in this kind of trial. Such trials can be double blinded and can involve crossover designs in which the patient is treated with alternating treatments, such as placebo-drug-placebo or one drug followed by another drug. As with any other clinical trial, a single-patient trial should be designed to permit objective comparison between treatments.
Pain is the most common symptom for which patients seek medical assistance.5 Pain associated with structural or psychophysiological disorders can arise from somatic, visceral, or neural structures. Somatic pain results from activation of receptors outside the brain and is transmitted to